U.S. Physical Therapy, Inc. USPH
Regular-session close
After hours · Nov 20, 4:26 PM ET
- YTD
- +22.85%
- 1 year
- +40.23%
5D -5.63 (-5.63%)
- Market cap
- 1.43B
- Revenue (ttm)
- 829.86M
- Profit margin
- 3.63%
- EPS (ttm)
- -1.33
- Shares out
- 14.93M
- Forward P/E
- 28.51
- Dividend
- 1.84 (1.95%)
- Ex-dividend date
- Nov 16, 2026
- YTD return
- +22.85%
- 1-year return
- +40.23%
- Volume
- 209.71K
- Avg volume
- 185.59K
- Open
- 94.82
- Previous close
- 94.32
- Day's range
- 94.99 – 96.76
- 52-week range
- 58.19 – 101.80
- Beta
- 1.13
- Analysts
- Buy
- Price target
- 111.50 (+16.2%)
- Earnings date
- Feb 24, 2027
Key statistics
- 50-day average
- 87.71
- 200-day average
- 77.52
- Enterprise value
- 2.15B
- PEG ratio
- 3.03
- Price / sales
- 1.73
- Price / book
- 3.34
- Payout ratio
- 1011.11%
- Revenue growth
- 13.10%
- Free cash flow
- 46.62M
- Total cash
- 39.69M
- Total debt
- 419.94M
- Return on equity
- 6.35%
- Short % of float
- 9.05%
Fundamental scorecard
14 of 25 checks passed on USPH’s reported financials
14of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 3 of 5
- Financial health 3 of 5
- Dividend 4 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 95.00
- Target (mean)
- 111.50
- Target (high)
- 122.00
- Strong buy4
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate 0.878.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | 0.87 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 0.756 | 0.80 | +0.04 | +5.82% |
| Aug 5, 2026 | Jun 30, 2026 | 0.814 | 0.75 | -0.06 | -7.86% |
| May 6, 2026 | Mar 31, 2026 | 0.55 | 0.46 | -0.09 | -16.36% |
| Feb 25, 2026 | Dec 31, 2025 | 0.67 | 0.67 | 0.00 | 0.00% |
| Nov 5, 2025 | Sep 30, 2025 | 0.67 | 0.66 | -0.01 | -1.49% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Barrington Research | main | Outperform | Outperform |
| Sep 11, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 10, 2026 | Barrington Research | main | Outperform | Outperform |
| Jun 24, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| May 13, 2026 | Barrington Research | main | Outperform | Outperform |
| May 8, 2026 | Citizens | main | Market Outperform | Market Outperform |
About U.S. Physical Therapy, Inc.
U.S. Physical Therapy, Inc., together with its subsidiaries, operates and manages outpatient physical therapy clinics. It operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. It offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. U.S. Physical Therapy, Inc. was founded in 1990 and is based in Houston, Texas.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Country
- United States
- Website
- usph.com
News
U.S. Physical Therapy Presented at the 18th Annual Southwest IDEAS Conference Barrington Research Maintains Outperform on US Physical Therapy, Raises Price Target to $122
Barrington Research Maintains Outperform on US Physical Therapy, Raises Price Target to $110
US Physical Therapy Q3 2026 Earnings Call Transcript US Physical Therapy Q3 Adj. EPS $0.80 Beats $0.76 Estimate, Sales $222.558M Beat $214.536M Estimate
Your note
Sign in to keep a note on USPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BINSTEIN RICHARD S | General Counsel | Sale | Mar 5, 2026 | 24,867 |
| GILMARTIN KATHLEEN A | Director | Stock Award(Grant) | May 18, 2026 | 27,092 |
| HARRIS BERNARD A. JR | Director | Stock Award(Grant) | May 18, 2026 | 20,914 |
| HENDRICKSON CAREY P | Chief Financial Officer | Stock Award(Grant) | Feb 22, 2026 | 37,808 |
| MOTSENBOCKER ANNE | Director | Stock Award(Grant) | May 18, 2026 | 9,812 |
| READING CHRISTOPHER J | Chief Executive Officer | Stock Award(Grant) | Feb 22, 2026 | 139,088 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 14.91% | 2,226,377 | 213.62M | Sep 29, 2026 |
| Neuberger Berman Group, LLC | 6.57% | 980,468 | 94.08M | Sep 29, 2026 |
| Copeland Capital Management, LLC | 6.30% | 940,528 | 90.24M | Sep 29, 2026 |
| Bahl & Gaynor LLC | 5.96% | 889,265 | 85.32M | Sep 29, 2026 |
| State Street Corporation | 4.82% | 719,455 | 69.03M | Sep 29, 2026 |
| Morgan Stanley | 4.47% | 667,015 | 64.00M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 888,029 | 85.21M | Sep 29, 2026 |
| ETF Series Solutions-Bahl & Gaynor Small/Mid Cap Income Growth ETF | 3.89% | 581,135 | 55.76M | Jun 29, 2026 |
| NEUBERGER BERMAN EQUITY FUNDS-Neuberger Genesis Fund | 3.78% | 563,592 | 54.08M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.25% | 484,591 | 46.50M | Jun 29, 2026 |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 2.81% | 419,350 | 40.24M | Sep 29, 2026 |
| Virtus Equity Trust-Virtus KAR Small-Cap Growth Fund | 2.64% | 393,615 | 37.77M | Jun 29, 2026 |
